How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

990 results for

Androgenic Alopecia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Androgenic Alopecia

. Differential Diagnosis IX. Grading: Rating of Hair Loss (Norwood and Hamilton Scale) Type I: Minimal hair line recession Type II: Symmetrical triangular over temples Type III: More at vertex and less at temple Type IV-V: Temple and vertex ; some crown loss Type VI: Contiguous frontal, vertex, and crown baldness Type VII: remains only over ears and occiput References Hamilton (1951) Ann NY Acad Dermatol 53:708-28 X. Labs: Women with Androgenetic Alopecia Indications (Not required in most cases) Irregular (...) : Androgenic Alopecia , Androgenetic Alopecia , Male-patterned Baldness From Related Chapters II. Definition Non-scarring androgen related III. Epidemiology Most common type of (esp. white men) Hereditary trait (positive ) Increasing with age Affects white men 30% at age 30, 40% at age 40, 50% at age 50 years Affects 38% of women over age 70 years IV. Course onset between ages 12 to 40 years evident by age 50 in >50% of patients V. Pathophysiology Androgen exposure shortens phase Men with increased

2018 FP Notebook

42. Minimally invasive treatment in female androgen alopecia: a systematic review

Minimally invasive treatment in female androgen alopecia: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect

2018 PROSPERO

43. Alopecia areata multiplex following autologous dermal micro-graft injection for treatment of androgenetic alopecia. (Abstract)

, through genome-wide association studies, gene expression analysis, and a C3H/HeJ mouse model of AA, the cytotoxic subset of CD8+NKG2D+ T cells was revealed to play a major role in AA development 2-4 . In contrast to AA, androgenetic alopecia (AGA) is believed to be caused by androgens on the hair cycles. Among other autologous transplantation procedures, autologous dermal micro-grafts have recently been used to treat AGA 5,6 . Herein, we report a case of AA that developed following an autologous (...) Alopecia areata multiplex following autologous dermal micro-graft injection for treatment of androgenetic alopecia. Alopecia areata (AA) is an autoimmune disease of the hair follicle (HF). Human anagen HFs are protected by immune privilege, defined in part as the absence of MHC class I antigen expression. AA is postulated to occur when the immune-privileged state of the HF is compromised 1 ; however, the immunopathogenesis, including autoantigens, of AA remain incompletely defined. Recently

2019 Journal of the European Academy of Dermatology and Venereology

44. Androgens, hair loss and eugenics: a tale of discovery and American social history. (Abstract)

Androgens, hair loss and eugenics: a tale of discovery and American social history. 25808933 2016 05 03 2018 12 02 1600-0625 24 6 2015 Jun Experimental dermatology Exp. Dermatol. Androgens, hair loss and eugenics: a tale of discovery and American social history. 412-3 10.1111/exd.12702 Ayob Shanti M SM Dermatology Department, Royal Hallamshire Hospital, Sheffield, UK. Messenger Andrew G AG Dermatology Department, Royal Hallamshire Hospital, Sheffield, UK. eng Biography Historical Article (...) Journal Article Portrait Denmark Exp Dermatol 9301549 0906-6705 0 Androgens IM Adult Aged Alopecia history physiopathology Androgens physiology Eugenics history History, 20th Century Hospitals, Psychiatric history Humans Institutionalization history Male Middle Aged Orchiectomy history United States Hamilton James B JB James Hamilton androgenetic alopecia androgens male balding testosterone 2015 03 19 2015 3 27 6 0 2015 3 27 6 0 2016 5 4 6 0 ppublish 25808933 10.1111/exd.12702

2015 Experimental Dermatology

45. Differential expression analysis of balding and non-balding dermal papilla microRNAs in Male Pattern Baldness with mRAP method. (Abstract)

Differential expression analysis of balding and non-balding dermal papilla microRNAs in Male Pattern Baldness with mRAP method.   Male pattern baldness or androgenetic alopecia is a common disorder affecting almost 50% of men throughout their lifetime, with androgens and genetics having significant contributing aetiologies. In contrast to the positive regulatory effect of androgens on body hair growth, they are thought to alter scalp hair follicle behaviour pathophysiologically, leading to male (...) pattern baldness. However, the exact mechanisms of this paradoxical action have not yet been elucidated. The role of microRNAs, a novel group of noncoding RNAs impacting almost every aspect of biology, health and human diseases, has been documented in hair follicle formation. In addition, their deregulation in cancer of the prostate, a target organ of androgens, has also been well established.To investigate the possible contribution of microRNAs in the pathophysiology of male pattern baldness.We

2011 British Journal of Dermatology

46. Digit-Length Ratios (2D:4D) as a Phenotypic Indicator of in Utero Androgen Exposure is Not Prognostic for Androgenic Alopecia: a Descriptive-Analytic Study of 1200 Iranian Men. Full Text available with Trip Pro

Digit-Length Ratios (2D:4D) as a Phenotypic Indicator of in Utero Androgen Exposure is Not Prognostic for Androgenic Alopecia: a Descriptive-Analytic Study of 1200 Iranian Men. The etiology of androgenic alopecia (AGA) involves several factors, including genetics, androgens, age and nutrition. Digit-length ratio of the index and ring finger (2D:4D) is an indicator of prenatal exposure to sex hormones. There is a paucity of studies that systemically review the possible positive predictive value (...) a multifactorial disease. Further, our findings suggest that increased in utero exposure to androgens as a fetus does not predispose men to develop AGA.

2016 Dermatology Reports

47. Androgen Receptor (AR) Gene (CAG)n and (GGN)n Length Polymorphisms and Symptoms in Young Males With Long-Lasting Adverse Effects After Finasteride Use Against Androgenic Alopecia Full Text available with Trip Pro

Androgen Receptor (AR) Gene (CAG)n and (GGN)n Length Polymorphisms and Symptoms in Young Males With Long-Lasting Adverse Effects After Finasteride Use Against Androgenic Alopecia Long-term adverse symptoms of men who used oral finasteride against androgenic alopecia have been recently described as post-finasteride syndrome (PFS).To determine whether (CAG)n-rs4045402 and (GGN)n-rs3138869 polymorphisms in the androgen receptor (AR) gene are implicated in PFS.AR polymorphisms were studied (...) sensitivity, scrotal discomfort, less pubic hair, loss of perceived perineal fullness, increased sperm density, involuntary muscle spasms, loss of muscle tone, increased weight (>2 kg), increased skin dryness, and onset of symptoms after finasteride use.This study showed that short and/or long (CAG)n and (GGN)n repeats had different frequencies according to symptoms reported by patients with PFS, likely reflecting the vast array of genes modulated by the AR. This study showed a U-curvilinear profile

2016 Sexual Medicine

48. Androgenetic Alopecia

their teens. Deep frontal recession and/or vertex balding may also start shortly after puberty although in most men the onset is later. About 50-60% of men are affected by the age of 50 increasing to about 80% by the age of 70 and beyond (4, 5). Hair loss progresses to a bald scalp (Norwood-Hamilton VI/VII) in 50-60% of men by the age of 70 (5). The prevalence of androgenetic alopecia is reportedly lower and its severity less among Asians, Native Americans and African-Americans compared to the European (...) , Belgium 9 Department of Dermatology, University of Bologna, Italy 10 Department of Dermatology and Allergy, Division of Evidence based Medicine, Charité – Universitätsmedizin, Berlin, Germany ABSTRACT Androgenetic alopecia is the most common hair loss disorder, affecting both men and women. Initial signs of androgenetic alopecia usually develop during teenage years leading to progressive hair loss with a pattern distribution. Moreover, its frequency increases with age and affects up to 80% Caucasian

2017 European Dermatology Forum

49. ENERGI-F701 for Female Hair Loss Treatment

Information provided by (Responsible Party): Energenesis Biomedical Co., Ltd. Study Details Study Description Go to Brief Summary: The objective of this study is to evaluate the efficacy and safety of ENERGI-F701 Solution in female subjects with hair loss. Condition or disease Intervention/treatment Phase Female Pattern Baldness Hair Loss Alopecia Drug: ENERGI-F701 Drug: Regaine Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment (...) -F701-01 First Posted: November 22, 2017 Last Update Posted: June 1, 2018 Last Verified: May 2018 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: Undecided Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Product Manufactured in and Exported from the U.S.: No Keywords provided by Energenesis Biomedical Co., Ltd.: Alopecia Hair Loss Female Pattern Baldness Additional relevant MeSH terms

2017 Clinical Trials

50. A Case Report of Cushing's Disease Presenting as Hair Loss Full Text available with Trip Pro

plethora, easy bruising, violaceous striae, hirsutism, and acne, the latter 2 signs reflecting androgen excess. Of interest, our patient presented with a chief complaint of hair loss, a common complaint in the general population that occurs with a greater frequency in patients with Cushing's disease and is attributed to androgenetic alopecia, but it is rarely the presenting symptom. (...) A Case Report of Cushing's Disease Presenting as Hair Loss Cushing's syndrome is a rare endocrine disorder that comprises a large group of signs and symptoms resulting from chronic exposure to excess corticosteroids. Most cases of Cushing's syndrome are due to increased adrenocorticotropic hormone production from a pituitary adenoma, which is referred to as Cushing's disease. Most of the signs and symptoms are nonspecific and common in the general population, making a diagnosis often

2017 Case reports in dermatology

51. Therapeutic Efficacy of a Combination Therapy of Topical 17α-Estradiol and Topical Minoxidil on Female Pattern Hair Loss: A Noncomparative, Retrospective Evaluation Full Text available with Trip Pro

Therapeutic Efficacy of a Combination Therapy of Topical 17α-Estradiol and Topical Minoxidil on Female Pattern Hair Loss: A Noncomparative, Retrospective Evaluation A variety of agents have been used to treat female pattern hair loss (FPHL), including topical minoxidil, topical 17α-estradiol, oral anti-androgen agents, and mineral supplements. Compared with these single agent regimens, combination therapies could be a better therapeutic option in expectation of superior treatment outcome.This (...) study was designed to determine the efficacy of a combination therapy consisting of topical 0.025% 17α-estradiol and 3% minoxidil in Korean patients with FPHL.Therapeutic efficacy was evaluated in 34 women who applied topical 0.025% 17α-estradiol and 3% minoxidil once daily for more than 6 months. Phototrichogram analysis was performed before and after therapy. The efficacy was evaluated with respect to total hair count, hair caliber (as assessed by phototrichogram analysis), and photographic

2017 Annals of dermatology

52. Study to Evaluate a Nutraceutical Supplement for Treatment of Hair Loss and Thinning in Females

consent agreement approved by the Institutional Review Board. Be able to complete and understand the various rating instruments in English. Sponsor approved global image assessment of degree of thinning / hair loss Exclusion Criteria: Clinical diagnosis of alopecia areata or scarring forms of alopecia Scalp hair loss on the treatment area, due to disease, injury, or medical therapy Subjects who are pregnant, planning to become pregnant or breastfeeding. A urine pregnancy test will be done to rule out (...) or condition (e.g., sunburn, tattoos) on the treatment area that, in the opinion of the Investigator, might put the subject at risk or interfere with the study conduct or evaluations. History of surgical correction of hair loss on the scalp/ Hair transplants. Use of any products or devices purported to promote scalp hair growth (e.g., finasteride or minoxidil) within the 30 days prior to the Baseline Visit. Use of anti-androgenic therapies (e.g., spironolactone, flutamide, cyproterone acetate, cimetidine

2017 Clinical Trials

53. Genetics and other factors in the aetiology of female pattern hair loss. Full Text available with Trip Pro

Genetics and other factors in the aetiology of female pattern hair loss. Pattern hair loss is the most common form of hair loss in both women and men. Male pattern hair loss, also termed male androgenetic alopecia (M-AGA), is an androgen-dependent trait that is predominantly genetically determined. Androgen-mediated mechanisms are probably involved in female pattern hair loss (FPHL) in some women but the evidence is less strong than in M-AGA; other non-androgenic pathways, including (...) environmental influences, may contribute to the aetiology. Genome-wide association studies have identified several genetic loci for M-AGA and have provided better insight into the underlying biology. However, the role of heritable factors in Female Pattern Hair Loss (FPHL) is largely unknown. Recently published studies have been restricted to candidate gene approaches and could not clearly identify any susceptibility locus/gene for FPHL but suggest that the aetiology differs substantially from that of M-AGA

2017 Experimental Dermatology

54. t-Flavanone Improves the Male Pattern of Hair Loss by Enhancing Hair-Anchoring Strength: A Randomized, Double-Blind, Placebo-Controlled Study. Full Text available with Trip Pro

t-Flavanone Improves the Male Pattern of Hair Loss by Enhancing Hair-Anchoring Strength: A Randomized, Double-Blind, Placebo-Controlled Study. trans-3,4'-Dimethyl-3-hydroxyflavanone (t-flavanone) is a derivative of astilbin that actively stimulates hair growth. The aim of the present study was to identify the mechanisms of action of t-flavanone on hair growth.A double-blind usage test was performed with healthy volunteers who had androgenic alopecia (AGA). The subjects were divided into three (...) groups with equal average baldness. The members in each group applied a vasodilator-containing hair lotion supplemented with either 0, 0.1, or 0.3% (wt) t-flavanone twice a day for 30 weeks. The efficacy of t-flavanone was evaluated based on the parietal global and microscopic images. At week 30, the anchoring strength of hair was measured by the average peak force required for plucking out a single hair in a non-bald area using a digital force gauge. Desmoglein expression in the cultured human hair

2016 Dermatology and therapy Controlled trial quality: uncertain

55. Are hand preference and sexual orientation possible predicting factors for finasteride adverse effects in male androgenic alopecia? Full Text available with Trip Pro

Are hand preference and sexual orientation possible predicting factors for finasteride adverse effects in male androgenic alopecia? Sexual side effects of finasteride seem to be redoubtable, being encountered not only during therapy but also after treatment cessation. Consequently, any possible clinical/paraclinical elements that might predict these adverse effects would be useful in the selection of a therapeutic strategy for male androgenic alopecia. Previous published studies show that some (...) compounds that interfere with sexual hormones can decrease sexual activation and response, according to hand preference (as reported for finasteride and tamoxifen) and according to sexual orientation (as noted for bicalutamide). Our preliminary published data and the arguments presented here suggest that these two individual parameters might be used by dermatologists in the therapeutic approach of male androgenic alopecia, so as to alert specific subsets of men, prior to treatment, of the potential

2016 Experimental Dermatology

56. Finasteride adverse effects in subjects with androgenic alopecia: A possible therapeutic approach according to the lateralization process of the brain. (Abstract)

Finasteride adverse effects in subjects with androgenic alopecia: A possible therapeutic approach according to the lateralization process of the brain. Nowadays, finasteride is a relatively frequently prescribed drug in the therapeutic management of male androgenic alopecia. The reported adverse effects are notable in some patients, consisting in signs and symptoms that are encountered both during finasteride administration and after treatment cessation. Clinical and imagistic data show (...) in dermatological practice, and to highlight its relevance in respect to therapeutic approach of male androgenic alopecia. As a possible therapeutic application, subjects having preference for a certain sexual orientation and/or predisposition for a given dominant hand could be advised before finasteride administration, that present an increased risk/sensitivity to develop adverse effects. Finally, even if finasteride and post-finasteride symptoms overlap to a large extent they should be, however, viewed

2016 Journal of Dermatological Treatment

57. Identification of a new plant extract for androgenic alopecia treatment using a non-radioactive human hair dermal papilla cell-based assay. Full Text available with Trip Pro

Identification of a new plant extract for androgenic alopecia treatment using a non-radioactive human hair dermal papilla cell-based assay. Androgenic alopecia (AGA) is a major type of human scalp hair loss, which is caused by two androgens: testosterone (T) and 5α-dihydrotestosterone (5α-DHT). Both androgens bind to the androgen receptor (AR) and induce androgen-sensitive genes within the human hair dermal papilla cells (HHDPCs), but 5α-DHT exhibits much higher binding affinity and potency (...) than T does in inducing the involved androgen-sensitive genes. Changes in the induction of androgen-sensitive genes during AGA are caused by the over-production of 5α-DHT by the 5α-reductase (5α-R) enzyme; therefore, one possible method to treat AGA is to inhibit this enzymatic reaction.RT-PCR was used to identify the presence of the 5α-R and AR within HHDPCs. A newly developed AGA-relevant HHDPC-based assay combined with non-radioactive thin layer chromatography (TLC) detection was used

2016 BMC Complementary and Alternative Medicine

58. Benign prostatic hyperplasia, metabolic syndrome and androgenic alopecia: Is there a possible relationship? Full Text available with Trip Pro

Benign prostatic hyperplasia, metabolic syndrome and androgenic alopecia: Is there a possible relationship? To evaluate the incidence of benign prostatic hyperplasia (BPH) and metabolic syndrome in patients with androgenetic alopecia (AGA) in comparison with those with no AGA, as several previous studies have reported inconsistent results of an association between metabolic syndrome and BPH with AGA.This cross-sectional study included 400 participants, divided into 300 patients diagnosed

2016 Arab journal of urology

59. Comparing Different Platelet Rich Plasma (PRP) Treatment Regimens for Management of Androgenic Alopecia

to investigate the most beneficial number and frequency ('schedule') of necessary PRP injections in men and women with androgenetic alopecia. Condition or disease Intervention/treatment Phase Androgenetic Alopecia Biological: Platelet Rich Plasma for 4 sessions Biological: Platelet rich plasma for 2 sessions Phase 4 Detailed Description: Androgenetic alopecia is the most common form of hair loss, affecting up to 50% of men and 21 million women in the US alone. Irrespective of gender, balding is known (...) , generating interest across a wide variety of medical specialties, such as orthopedics, dentistry, ophthalmology, and dermatology. Several recently published studies have demonstrated efficacy in treating androgenetic alopecia (aka male or female patterned hair loss), but each varies in the treatment protocol, and there is no evidence-based data to date guiding the dosing parameters of and intervals between injection sessions. We propose a single-center, single-blinded randomized pilot trial

2016 Clinical Trials

60. Pharmacokinetics/ Pharmacodynamics and Safety of DA-4001 in Healthy Male Subjects With Androgenic Alopecia

information Ages Eligible for Study: 19 Years to 65 Years (Adult, Older Adult) Sexes Eligible for Study: Male Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Male, aged between 19 and 65 years, clinically healthy BMI between 18.5kg/m2 and 27kg/m2 Clinical history of Androgenic Alopecia Exclusion Criteria: Subject has any dermatological disorders of the scalp Subject has a history of hair transplants, hair weaves Subject has hypersensitivity to previously prescribed minoxidil or finasteride (...) Pharmacokinetics/ Pharmacodynamics and Safety of DA-4001 in Healthy Male Subjects With Androgenic Alopecia Pharmacokinetics/ Pharmacodynamics and Safety of DA-4001 in Healthy Male Subjects With Androgenic Alopecia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100

2016 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>